A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogenicity in the different study cohorts in open-label phase.

Study Overview

• Status: Completed
• Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
• Intervention / Treatment: Biological: Ad26.COV2.S; Other: Placebo

Detailed Description

The aim of the COVID-19 vaccine clinical development program is to develop a safe and effective vaccine for the prevention of COVID-19. Ad26.COV2.S, a COVID-19 vaccine based on a human replication-incompetent Ad26 vector, constructed to encode the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus spike (S) protein, is being developed. The study will consist of: a screening phase (up to 28 days), study period (60-week), and a long-term follow-up period (1 additional year). The total study duration will be maximum 2 years and 3 months for the participants. Assessments for efficacy (COVID-19 signs and symptoms, etc.), immunogenicity (such as humoral immune responses), and safety (such as adverse events [AEs] monitoring) will be performed throughout the study.

• Study Type: Interventional
• Enrollment (Actual): 31835
• Phase: Phase 3

Expanded Access

No longer available outside the clinical trial. See expanded access record.

Contacts and Locations

Study Locations

• Belgium
  • Alken, Belgium, 3570
    • Anima
  • Antwerpen, Belgium, 2000
    • Institute Of Tropical Medicine Antwerp
  • Gent, Belgium, 9000
    • Center for Vaccinology (CEVAC)
  • Leuven, Belgium, 3000
    • UZ Leuven
  • Mechelen, Belgium, 2800
    • Az Sint-Maarten
  • Namur, Belgium, 5101
    • Private Practice RESPISOM Namur
• Brazil
  • Porto Alegre, Brazil, 91350 200
    • Hospital Nossa Senhora da Conceicao S A
  • Rio de Janeiro, Brazil, 20221-160
    • Ministerio da Saude - Hospital dos Servidores do Estado - RJ
  • Rio de Janeiro, Brazil, 21040-900
    • Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ
  • Sao Paulo, Brazil, 01246-900
    • Instituto de Infectologia Emilio Ribas
  • Sao Paulo, Brazil, 02141-000
    • Centro de Referência e Treinamento DST/AIDS
• Colombia
  • Armenia, Colombia
    • Fundacion Cardiomet Cequin
  • Barranquilla, Colombia, 80020
    • IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S.
  • Bogota, Colombia
    • Asistencia Cientifica de Alta Complejidad S.A.S
  • Cali, Colombia, 760042
    • Centro Medico Imbanaco de Cali S.A.
  • Santa Marta, Colombia, 470001
    • T Y C Inversiones S A S Grupsalud
• France
  • Montpellier, France, 34295 cedex 05
    • CHU de Montpellier Hopital Saint Eloi
  • Paris, France, 75014
    • Hopital Cochin
  • Paris Cedex 12, France, 75571
    • Hopital Saint-Antoine
  • Pessac, France, 33604
    • Groupe Hospitalier Sud Hôpital Haut-Leveque Service d'hematologie
  • Saint-Etienne Cedex 2, France, 42055
    • CHU Saint Etienne Hopital Nord
  • Toulouse, France, 31054
    • Hopital Rangueil
  • Toulouse Cedex 09, France, 31059
    • Hopital Purpan
  • Vandoeuvre les Nancy, France, 54511
    • Hôpital de Brabois Adultes
• Germany
  • München, Germany, 81675
    • Klinikum rechts der Isar der TU München
• Philippines
  • Bacolod, Philippines, 6100
    • Riverside Medical Center
  • Iloilo City, Philippines, 5000
    • West Visayas State University Medical Center
  • Makati, Philippines, 1230
    • Tropical Disease Foundation
  • Manila, Philippines, 1000
    • Medical Center Manila
  • Manila, Philippines, 1000
    • Makati Medical Center
• South Africa
  • Cape Town, South Africa, 7500
    • TREAD Research Tygerberg Hospital
  • Cape Town, South Africa, 7700
    • Centre of Tuberculosis Research Innovation
  • Johannesburg, South Africa, 1501
    • Worthwhile Clinical Trials
  • Kempton Park, South Africa, 1619
    • Peermed Clinical Trial Centre
  • Moloto, South Africa, 1022
    • Dr AA Mahomed Medical Centre
  • Pretoria, South Africa, 0002
    • Vx Pharma
  • Somerset West, South Africa, 7130
    • Dr J.M. Engelbrecht Trial Site
  • Western Cape, South Africa, 7626
    • Be Part Yoluntu Centre
• Spain
  • Badalona, Spain, 08916
    • Hosp. Univ. Germans Trias I Pujol
  • Barcelona, Spain, 08023
    • Hosp. Quiron Barcelona
  • Barcelona, Spain, 8035
    • Hosp Univ Vall D Hebron
  • Barcelona, Spain, 08063
    • Hosp Clinic de Barcelona
  • Madrid, Spain, 28027
    • Clinica Univ. de Navarra
  • Madrid, Spain, 28006
    • Hosp. Univ. de La Princesa
  • Madrid, Spain, 28046
    • Hosp. Univ. de La Paz
  • Madrid, Spain, 28223
    • Hosp. Quiron Madrid Pozuelo
  • Pamplona, Spain, 31008
    • Clinica Univ. de Navarra
• United Kingdom
  • Birmingham, United Kingdom, B15 2GW
    • Queen Elizabeth Hospital
  • Brecon, United Kingdom, LD3 0UL
    • Powys Teaching Local Health Board - Bronllys Hospital
  • Brighton, United Kingdom, BN2 5BE
    • Brighton & Sussex University Hospitals NHS Trust
  • Bristol, United Kingdom, BS2 8HW
    • University Hospitals Bristol NHS Trust
  • Cambridge, United Kingdom, CB2 0QQ
    • Cambridge University Hospitals NHS Foundation Trust
  • Dundee, United Kingdom, DD1 9SY
    • Ninewells Hospital
  • Hampstead, United Kingdom, NW3 2QG
    • Royal Free Hospital
  • Leicester, United Kingdom
    • Leicester Royal Infirmary
  • London, United Kingdom, W2 1NY
    • Imperial College London and Imperial College Healthcare NHS Trust
  • London, United Kingdom, SE1 9RT
    • Guy's and St Thomas' Hospital
  • Manchester, United Kingdom, M13 9WL
    • Central Manchester University Hospitals NHS Foundation Trust
  • Newcastle upon Tyne, United Kingdom, NE1 4LP
    • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Oxford, United Kingdom, OX3 7JX
    • University of Oxford
  • Plymouth, United Kingdom, PL6 8DH
    • Derriford Hospital
  • Sheffield, United Kingdom, S10 2SB
    • Sheffield Teaching Hospitals NHS Foundation Trust
  • Southampton, United Kingdom, SO16 6YD
    • Southampton General Hospital
• United States
  • Alabama
    • Vestavia Hills, Alabama, United States, 35216
      • Achieve Clinical Research, LLC
  • Arizona
    • Phoenix, Arizona, United States, 85018
      • Hope Research Institute
    • Phoenix, Arizona, United States, 85020
      • Central Phoenix Medical Clinic
    • Tucson, Arizona, United States, 85712
      • Quality of Life Medical & Research Center, LLC
    • Tucson, Arizona, United States, 85712
      • Synexus Clinical Research US Inc
  • Arkansas
    • Little Rock, Arkansas, United States, 72211
      • Woodland International Research Group
  • California
    • Cerritos, California, United States, 90703
      • Synexus Clinical Research US Inc
    • Chula Vista, California, United States, 91911
      • eStudySite
    • Long Beach, California, United States, 90806
      • Ark Clinical Research
    • Los Angeles, California, United States, 90069
      • Anthony Mills Medical, Inc
    • Sacramento, California, United States, 95684
      • Benchmark Research
    • San Diego, California, United States, 92103
      • Artemis Institute for Clinical Research
  • Colorado
    • Wheat Ridge, Colorado, United States, 80033
      • Paradigm Clinical Research Centers, Inc.
  • Florida
    • Atlantis, Florida, United States, 33462
      • JEM Research LLC
    • Coral Gables, Florida, United States, 33134
      • Prestige Clinical Research Center, Inc.
    • DeLand, Florida, United States, 32720
      • Avail Clinical Research, LLC
    • Hallandale Beach, Florida, United States, 33009
      • Velocity Clinical Research, Hallandale Beach
    • Jupiter, Florida, United States, 33458
      • Health Awareness Inc.
    • Lake Worth, Florida, United States, 33461
      • Altus Research, Inc
    • Melbourne, Florida, United States, 32940
      • Compass Research, Melbourne
    • Miami, Florida, United States, 33135
      • Suncoast Research Group
    • North Miami, Florida, United States, 33161
      • Behavioral Clinical Research , Inc
    • Orlando, Florida, United States, 32806
      • Clinical NeuroScience Solutions Inc
    • Port Orange, Florida, United States, 32127
      • Progressive Medical Research
    • Saint Petersburg, Florida, United States, 33709
      • Meridien Research
    • West Palm Beach, Florida, United States, 33409
      • Palm Beach Research Center
  • Georgia
    • Atlanta, Georgia, United States, 30331
      • Atlanta Center for Medical Research
    • Eatonton, Georgia, United States, 31204
      • Accel Research Sites
  • Illinois
    • Chicago, Illinois, United States, 60640
      • Great Lakes Clinical Trials
    • Chicago, Illinois, United States, 60637
      • The University of Chicago Medicine
  • Indiana
    • South Bend, Indiana, United States, 46617-2808
      • The South Bend Clinic Center for Research
  • Kansas
    • Newton, Kansas, United States, 67114
      • Heartland Research Associates, LLC
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • University Of Kentucky
  • Louisiana
    • Lake Charles, Louisiana, United States, 70601
      • Centex Studies, Inc.
    • New Orleans, Louisiana, United States, 70121
      • Ochsner Clinic Foundation
  • Maryland
    • Elkridge, Maryland, United States, 21075
      • Centennial Medical Group
    • Rockville, Maryland, United States, 20850
      • Optimal Research
    • Rockville, Maryland, United States, 20854
      • Meridian Clinical Research, LLC
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Henry Ford Health Systems
    • Grand Rapids, Michigan, United States, 49503
      • Cherry Street Services, Inc.
  • Missouri
    • Saint Louis, Missouri, United States, 63110-1035
      • Washington University School of Medicine
  • New Jersey
    • Berlin, New Jersey, United States, 08009
      • Hassman Research Institute, LLC.
    • Neptune, New Jersey, United States, 07753
      • Jersey Shore University Medical Center
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • MedPharmics, LLC
  • New York
    • Endwell, New York, United States, 13760
      • Regional Clinical Research, Inc.
    • Endwell, New York, United States, 13760
      • Meridian Clinical Research, LLC
    • Rochester, New York, United States, 14618
      • Allergy Asthma Immunology of Rochester, PC (AAIR) - Research Center
    • Staten Island, New York, United States, 10312
      • Richmond Behavioral Associates
  • North Carolina
    • Charlotte, North Carolina, United States, 28207
      • American Health Network, LLC
    • Wilmington, North Carolina, United States, 28401
      • Wilmington Health Associates
  • Ohio
    • Cincinnati, Ohio, United States, 45212
      • CTI Clinical Trial and Consulting Services
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • Lynn Health Science Institute
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Medical University of South Carolina
    • Mount Pleasant, South Carolina, United States, 29464
      • Coastal Carolina Research Center
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Centennial Medical Center
  • Texas
    • Houston, Texas, United States, 77058
      • Centex Studies, Inc.
    • Houston, Texas, United States, 77073
      • Centex Studies, Inc.
    • Houston, Texas, United States, 77081
      • Texas Center for Drug Development Inc
    • McAllen, Texas, United States, 78504
      • Centex Studies, Inc.
    • San Antonio, Texas, United States, 78229
      • Endeavor Clinical Trials, LLC
    • Webster, Texas, United States, 77598
      • Tranquility Clinical Research
  • Utah
    • Salt Lake City, Utah, United States, 84107
      • JBR Clinical Research
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Alliance for Multispeciality Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies
• All participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration
• Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine
• Must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study
• Must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (eCOA) (that is, the coronavirus disease-2019 [COVID 19] signs and symptoms surveillance question, the e-Diary, and the electronic patient-reported outcomes (ePROs)

Exclusion Criteria:

• Participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (>=) 38.0 degree Celsius (100.4-degree Fahrenheit) within 24 hours prior to the planned first dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor
• Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients
• Participant received or plans to receive: (a) licensed live attenuated vaccines - within 28 days before or after planned administration of study vaccine; and (b) other licensed (not live) vaccines - within 14 days before or after planned administration of study vaccine
• Participant previously received a coronavirus vaccine
• Participant received an investigational drug within 30 days (including investigational drugs for prophylaxis of COVID-19) or used an invasive investigational medical device within 30 days or received investigational immunoglobulin (Ig) or investigational monoclonal antibodies within 3 months, or received convalescent serum for COVID-19 treatment within 4 months or received an investigational vaccine (including investigational Adenoviral-vectored vaccines) within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ad26.COV2.S; Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1 and Day 57. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.	Biological: Ad26.COV2.S; Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.; Other Names: JNJ-78436735; Ad26COVS1; VAC31518
Placebo Comparator: Placebo; Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.	Biological: Ad26.COV2.S; Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.; Other Names: JNJ-78436735; Ad26COVS1; VAC31518; Other: Placebo; Placebo will be administered as IM injection on Day 1 and Day 57.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 in Seronegative Participants With Onset at Least 14 Days After the Second Vaccination	Molecularly confirmed moderate to severe/critical COVID-19 was defined as a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positive reverse transcription/polymerase chain reaction (RT-PCR) or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample. Moderate included one sign or symptom such as respiratory rate >=20 breaths per minute (min) and symptoms such as shortness of breath or two signs or symptoms such as heart rate >=90 beats/min and symptoms such as cough from a list of signs and symptoms and severe/critical included one of the following signs and symptoms: respiratory rate >=30 breaths/min, heart rate >=125 beats/min, oxygen saturation (SpO2) <=93 percent (%) on room air at sea level respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, admission to Intensive Care Unit (ICU), death defined as per FDA guidance.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Serostatus With Onset At Least 1 Day After the First Day 1 Vaccination	Molecularly confirmed moderate to severe/critical COVID-19 was defined as a SARS-CoV-2 positive RT-PCR or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample. Moderate included one sign or symptom such as respiratory rate greater than or equal to (>=) 20 breaths per minute and symptoms such as shortness of breath or two signs or symptoms such as heart rate >= 90 beats per min and symptoms such as cough from a list of signs and symptoms and severe/critical included one of the following signs and symptoms: respiratory rate >=30 breaths/minute, heart rate >=125 beats/minute, SpO2 less than or equal to (<=) 93% on room air at sea level respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, admission to the ICU, death defined as per US Food and Drug Administration (FDA) guidance.	From at least 1 day after first vaccination on Day 1 (Day 2) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Serostatus With Onset at Least 14 Days After the Second Vaccination	Molecularly confirmed moderate to severe/critical COVID-19 was defined as a SARS-CoV-2 positive RT-PCR or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample. Moderate included one sign or symptom such as respiratory rate >= 20 breaths per minute and symptoms such as shortness of breath or two signs or symptoms such as heart rate >= 90 beats per min and symptoms such as cough from a list of signs and symptoms and severe/critical included one of the following signs and symptoms: respiratory rate >=30 breaths/minute, heart rate >=125 beats/minute, SpO2 <= 93% on room air at sea level respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, admission to the ICU, death defined as per FDA guidance.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 in Seronegative Participants With Onset at Least 1 Day After the First Day 1 Vaccination	Molecularly confirmed moderate to severe/critical COVID-19 was defined as a SARS-CoV-2 positive RT-PCR or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample. Moderate included one sign or symptom such as respiratory rate >= 20 breaths per minute and symptoms such as shortness of breath or two signs or symptoms such as heart rate >= 90 beats per min and symptoms such as cough from a list of signs and symptoms and severe/critical included one of the following signs and symptoms: respiratory rate >=30 breaths/minute, heart rate >=125 beats/minute, SpO2 <= 93% on room air at sea level respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, admission to the ICU, death defined as per FDA guidance.	From at least 1 day after first vaccination on Day 1 (Day 2) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 With Onset at Least 14 Days After the First Day 1 Vaccination	Molecularly confirmed moderate to severe/critical COVID-19 was defined as a SARS-CoV-2 positive RT-PCR or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample. Moderate included one sign or symptom such as respiratory rate >= 20 breaths per minute and symptoms such as shortness of breath or two signs or symptoms such as heart rate >= 90 beats per min and symptoms such as cough from a list of signs and symptoms and severe/critical included one of the following signs and symptoms: respiratory rate >=30 breaths/minute, heart rate >=125 beats/minute, SpO2 <= 93% on room air at sea level respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, admission to the ICU, death defined as per FDA guidance.	From at least 14 days after first vaccination on Day 1 (Day 15) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 With Onset at Least 28 Days After the First Day 1 Vaccination	Molecularly confirmed moderate to severe/critical COVID-19 was defined as a SARS-CoV-2 positive RT-PCR or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample. Moderate included one sign or symptom such as respiratory rate >= 20 breaths per minute and symptoms such as shortness of breath or two signs or symptoms such as heart rate >= 90 beats per min and symptoms such as cough from a list of signs and symptoms and severe/critical included one of the following signs and symptoms: respiratory rate >=30 breaths/minute, heart rate >=125 beats/minute, SpO2 <= 93% on room air at sea level respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, admission to the ICU, death defined as per FDA guidance.	From at least 28 days after the first vaccination on Day 1 (Day 29) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With First Occurrence of COVID-19 Requiring Medical Intervention With Onset at Least 14 Days After the Second Vaccination	Number of participants with first occurrence of COVID-19 requiring medical intervention (such as a composite endpoint of hospitalization, ICU admission, mechanical ventilation, and extracorporeal membrane oxygenation [ECMO]), linked to objective measures such as decreased oxygenation, X-ray or computed tomography [CT] findings and linked to any molecularly confirmed, COVID-19 with onset at least 14 days post second vaccination were reported.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)
Double Blind Phase: Area Under the Curve (AUC) of SARS-CoV-2 Viral Load as Assessed by Quantitative RT-PCR in Participants With Molecularly Confirmed Symptomatic COVID-19 With Onset at Least 14 Days After Second Vaccination	AUC of SARS-CoV-2 viral load was assessed in confirmed COVID-19 cases using RT-PCR. Nasal swabs were used to detect and/or quantify SARS-CoV-2. Due to change in the planned analysis, data was collected and analyzed for participants with molecularly confirmed symptomatic COVID-19 regardless of severity that is mild, moderate or severe and was not collected and analyzed separately for moderate to severe cases.	From Day 71 up to end of the COVID-19 episode (up to 90 days)
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Mild COVID-19 With Onset at Least 14 Days After the Second Vaccination	Molecularly confirmed mild Covid-19 was defined as a SARS-CoV-2 positive RT-PCR or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample and one of the following signs and symptoms: fever (>=38 degree Celsius or >=100.4 degree Fahrenheit), sore throat, malaise (loss of appetite, generally unwell, fatigue, physical weakness), headache, muscle pain (myalgia), gastrointestinal symptoms, cough, chest congestion, runny nose, wheezing, skin rash, eye irritation or discharge, chills, new or changing olfactory or taste disorders, red or bruised looking feet or toes, or shaking chills or rigors.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed COVID-19 Defined by the US FDA Harmonized Case Definition With Onset at Least 14 Days After the Second Vaccination	Molecularly confirmed COVID-19 was defined as SARS-CoV-2 positive RT-PCR or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample; and COVID-19 symptoms consistent with those defined by the US FDA harmonized case definition at the time of finalization of the study protocol: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19 With Onset at Least 14 Days After the Second Vaccination	BOD is a weighted version of the mild, moderate, and severe/critical vaccine efficacies and was evaluated based on the first occurrence of molecularly confirmed COVID-19, including mild, moderate or severe/critical COVID-19 case.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With Serologic Conversion Between Day 71 up to Unblinding Visit Using an Enzyme-linked Immunosorbent Assay (ELISA)	Number of participants with serologic conversion between Day 71 up to unblinding visit using an ELISA were reported. Due to change in planned analysis, data was collected and analyzed between Day 71 up to unblinding visit instead of from baseline to unblinding visit.	From Day 71 up to unblinding visit (7.2 months)
Double Blind Phase: Number of Participants With Asymptomatic Infection Detected By Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) With Onset at Least 14 Days After the Second Vaccination	Number of participants with asymptomatic infection detected by RT-PCR with onset at least 14 days after the second vaccination (Day 71) were reported.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With First Occurrence of SARS-CoV-2 Infection (Serologically and/or Molecularly Confirmed) With Onset at Least 14 Days After the Second Vaccination	Number of participants with first occurrence of SARS-CoV-2 infection (serologically and/or molecularly confirmed) with onset at least 14 days after the second vaccination (Day 71) were reported.	From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With Serious Adverse Events (SAEs)	An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the vaccine. SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.	From Day 1 up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With Adverse Events of Special Interest (AESIs)	Number of participants with AESIs were reported. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Thrombosis with Thrombocytopenia Syndrome (TTS), a syndrome characterized by a combination of both a thrombotic event and thrombocytopenia, was considered to be an AESI in this study. A suspected TTS case was defined as: Thrombotic events: suspected deep vessel venous or arterial thrombotic events; Thrombocytopenia, defined as platelet count below 150,000/micro liter.	From Day 1 up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With Medically-Attended Adverse Events (MAAEs)	An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the vaccine. MAAEs were defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason.	From Day 1 up to 7.2 months
Double-Blind: Number of Participants With MAAEs Leading to Study Discontinuation	An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the vaccine. MAAEs were defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason.	From Day 1 up to end of double blind phase (7.2 months)
Double Blind Phase: Number of Participants With Solicited Local Adverse Events (AEs) During 7 Days Following Each Vaccination	An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the vaccine. Participants who were enrolled in safety subset (SS) were asked to note in the e-Diary occurrences of injection site pain/tenderness, erythema, and swelling at the study vaccine injection site daily for 7 days post each vaccination (day of vaccination and the subsequent 7 days).	7 days after first vaccination on Day 1 (up to Day 8), 7 days after second vaccination on Day 57 (up to Day 64)
Double Blind Phase: Number of Participants With Solicited Systemic AEs During 7 Days Following Each Vaccination	An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the vaccine. Participants who were enrolled in safety subset were instructed on how to record daily temperature using a thermometer provided for home use. Participants recorded temperature in e-Diary in evening of the day of vaccination, and then daily for next 7 days approximately at same time each day. If more than 1 measurement was made on any given day, the highest temperature of that day was recorded in e-Diary. Fever was defined as endogenous elevation of body temperature >= 38.0 degree Celsius or >=100.4-degree Fahrenheit, as recorded in at least 1 measurement. Participants also noted the signs and symptoms in e-Diary on a daily basis for 7 days post each vaccination (day of vaccination and subsequent 7 days), for the following events: fatigue, headache, nausea, myalgia.	7 days after first vaccination on Day 1 (up to Day 8), 7 days after second vaccination on Day 57 (up to Day 64)
Double Blind Phase: Number of Participants With Unsolicited Adverse Events (AEs) During 28 Days Post Each Vaccination	An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the vaccine. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.	28 days after first vaccination on Day 1 (up to Day 29), 28 days after second vaccination on Day 57 (up to Day 85)
Double Blind Phase: SARS-CoV-2 Binding Antibodies Assessed by ELISA	Binding antibodies to SARS-CoV-2 S protein as assessed by ELISA to measure humoral immune response was reported. The lower limit of quantification (LLOQ) was 50.3 ELISA units per milliliter (EU/mL). A sample was considered positive if the value was strictly greater than the LLOQ (>LLOQ).	At Baseline (Day 1), Days 29, 57 and 71

Collaborators and Investigators

• Sponsor: Janssen Vaccines & Prevention B.V.
• Investigators: Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial, Janssen Vaccines & Prevention B.V.

Publications and helpful links

General Publications

• Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guinazu J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Erratum In: Lancet Infect Dis. 2023 Jan;23(1):e1. doi: 10.1016/S1473-3099(22)00739-3.

Study record dates

Study Major Dates

• Study Start (Actual): November 12, 2020
• Primary Completion (Actual): June 18, 2023
• Study Completion (Actual): June 18, 2023

Study Registration Dates

• First Submitted: November 3, 2020
• First Submitted That Met QC Criteria: November 3, 2020
• First Posted (Actual): November 4, 2020

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 31, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19
• Other Study ID Numbers: CR108916; 2020-003643-29 (EudraCT Number); VAC31518COV3009 (Other Identifier: Janssen Vaccines & Prevention B.V.)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No